These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9113369)
1. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Gargett CE; Wiley JS Br J Pharmacol; 1997 Apr; 120(8):1483-90. PubMed ID: 9113369 [TBL] [Abstract][Full Text] [Related]
2. ATP, a partial agonist for the P2Z receptor of human lymphocytes. Gargett CE; Cornish JE; Wiley JS Br J Pharmacol; 1997 Nov; 122(5):911-7. PubMed ID: 9384508 [TBL] [Abstract][Full Text] [Related]
3. Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Humphreys BD; Virginio C; Surprenant A; Rice J; Dubyak GR Mol Pharmacol; 1998 Jul; 54(1):22-32. PubMed ID: 9658186 [TBL] [Abstract][Full Text] [Related]
4. Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel. Wiley JS; Gargett CE; Zhang W; Snook MB; Jamieson GP Am J Physiol; 1998 Nov; 275(5):C1224-31. PubMed ID: 9814970 [TBL] [Abstract][Full Text] [Related]
5. Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. Jamieson GP; Snook MB; Thurlow PJ; Wiley JS J Cell Physiol; 1996 Mar; 166(3):637-42. PubMed ID: 8600168 [TBL] [Abstract][Full Text] [Related]
6. Activation of the P2Z/P2X7 receptor in human lymphocytes produces a delayed permeability lesion: involvement of phospholipase D. Fernando KC; Gargett CE; Wiley JS Arch Biochem Biophys; 1999 Feb; 362(2):197-202. PubMed ID: 9989927 [TBL] [Abstract][Full Text] [Related]
7. Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Shemon AN; Sluyter R; Conigrave AD; Wiley JS Br J Pharmacol; 2004 Jul; 142(6):1015-9. PubMed ID: 15210579 [TBL] [Abstract][Full Text] [Related]
8. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Gu B; Bendall LJ; Wiley JS Blood; 1998 Aug; 92(3):946-51. PubMed ID: 9680363 [TBL] [Abstract][Full Text] [Related]
9. The ATP4- receptor-operated channel (P2Z class) of human lymphocytes allows Ba2+ and ethidium+ uptake: inhibition of fluxes by suramin. Wiley JS; Chen R; Jamieson GP Arch Biochem Biophys; 1993 Aug; 305(1):54-60. PubMed ID: 7688203 [TBL] [Abstract][Full Text] [Related]
10. The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Wiley JS; Chen JR; Snook MB; Jamieson GP Br J Pharmacol; 1994 Jul; 112(3):946-50. PubMed ID: 7921625 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. Baraldi PG; del Carmen Nuñez M; Morelli A; Falzoni S; Di Virgilio F; Romagnoli R J Med Chem; 2003 Apr; 46(8):1318-29. PubMed ID: 12672232 [TBL] [Abstract][Full Text] [Related]
12. 1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle. Brozinick JT; Reynolds TH; Dean D; Cartee G; Cushman SW Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):533-40. PubMed ID: 10215590 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of voltage-gated Ca2+ channel activity in small cell lung carcinoma by the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz ine) . Williams CL; Porter RA; Phelps SH Biochem Pharmacol; 1995 Dec; 50(12):1979-85. PubMed ID: 8849323 [TBL] [Abstract][Full Text] [Related]
14. Induction of the P2z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. Humphreys BD; Dubyak GR J Immunol; 1996 Dec; 157(12):5627-37. PubMed ID: 8955215 [TBL] [Abstract][Full Text] [Related]
15. Transduction mechanisms of P2Z purinoceptors. Wiley JS; Chen JR; Snook MS; Gargett CE; Jamieson GP Ciba Found Symp; 1996; 198():149-60; discussion 160-5. PubMed ID: 8879824 [TBL] [Abstract][Full Text] [Related]
16. P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes. Peng L; Bradley CJ; Wiley JS Chin Med J (Engl); 1999 Apr; 112(4):356-62. PubMed ID: 11593539 [TBL] [Abstract][Full Text] [Related]
17. A novel pathway for the activation of phospholipase D by P2z purinergic receptors in BAC1.2F5 macrophages. el-Moatassim C; Dubyak GR J Biol Chem; 1992 Nov; 267(33):23664-73. PubMed ID: 1331096 [TBL] [Abstract][Full Text] [Related]
18. Effects of antagonists at the human recombinant P2X7 receptor. Chessell IP; Michel AD; Humphrey PP Br J Pharmacol; 1998 Jul; 124(6):1314-20. PubMed ID: 9720806 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of M3 muscarinic acetylcholine receptor-mediated Ca2+ influx and intracellular Ca2+ mobilization in neuroblastoma cells by the Ca2+/calmodulin-dependent protein kinase inhibitor 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-trosyl]-4-phenylpiperazin e (KN-62). Puhl HL; Raman PS; Williams CL; Aronstam RS Biochem Pharmacol; 1997 Apr; 53(8):1107-14. PubMed ID: 9175715 [TBL] [Abstract][Full Text] [Related]
20. Complexities of measuring antagonist potency at P2X(7) receptor orthologs. Hibell AD; Thompson KM; Xing M; Humphrey PP; Michel AD J Pharmacol Exp Ther; 2001 Mar; 296(3):947-57. PubMed ID: 11181928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]